Provided by Tiger Trade Technology Pte. Ltd.

Aethlon Medical

2.73
+0.03001.11%
Post-market: 2.69-0.0392-1.44%19:41 EDT
Volume:37.47K
Turnover:102.87K
Market Cap:1.94M
PE:-0.09
High:2.82
Open:2.81
Low:2.69
Close:2.70
52wk High:105.00
52wk Low:2.63
Shares:711.10K
Float Shares:707.00K
Volume Ratio:0.87
T/O Rate:5.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-31.4508
EPS(LYR):-428.8747
ROE:-160.91%
ROA:-76.69%
PB:0.37
PE(LYR):-0.01

Loading ...

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Johnson & Johnson (JNJ) and Phreesia (PHR)

TIPRANKS
·
Jun 12

Aethlon Medical posts corporate presentation on Hemopurifier platform targeting cancer, viral threats, transplant

Reuters
·
Jun 12

Aethlon Medical Reports Fiscal 2026 Results, Clinical Progress

TIPRANKS
·
Jun 11

Aethlon Medical Q4 EPS $0.40 Beats $(2.02) Estimate

Benzinga Earnings
·
Jun 11

Aethlon Medical FY26 net loss narrows 46.58% to $7.2 million

Reuters
·
Jun 11

Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

THOMSON REUTERS
·
Jun 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jun 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jun 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jun 05

Aethlon Medical updates ATM program, authorizes up to $542,716 in additional common stock sales

Reuters
·
Jun 04

Aethlon Medical to release fiscal year-end results, host conference call

Reuters
·
Jun 02

Aethlon Medical Inc: Hemopurifier, Though Investigational, Showed Rapid Viral Reduction in One Ebola Patient in Germany

THOMSON REUTERS
·
May 21

Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness

THOMSON REUTERS
·
May 21

Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025

Reuters
·
Mar 28

Aethlon Medical advances to final cohort in AEMD-2022-06 trial

TIPRANKS
·
Mar 24

Aethlon Medical opens final cohort in Hemopurifier oncology trial after DSMB review finds no safety concerns

Reuters
·
Mar 24

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive Dsmb Review

THOMSON REUTERS
·
Mar 24

Aethlon Medical Inc: Dsmb Also Stated That "No Safety Concerns Were Noted With Hemopurifier Device/Procedure"

THOMSON REUTERS
·
Mar 24

Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity

TIPRANKS
·
Mar 17

Aethlon Medical says all pre-funded warrants have been exercised

Reuters
·
Mar 17